Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q4 FY19 results · Jan–Mar 2019
Glenmark Pharmaceuticals reported revenue from operations of ₹2,563.47 crore and net profit of ₹161.66 crore for Q4 FY19 (Jan–Mar 2019), on a consolidated basis.
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,563.47 | — | — | 2,555.05 | +0.3% |
| Other income | 39.06 | — | — | (109.02) | Turned profit |
| Total income | 2,602.53 | — | — | 2,446.03 | +6.4% |
| Profit before tax | 240.31 | — | — | 154.03 | +56.0% |
| Net profit for the period | 161.66 | — | — | 116.34 | +39.0% |
| EPS, basic (₹) | 5.73 | — | — | 4.12 | +39.1% |
| Net margin (%) | 6.3 | — | 4.6 |
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,587.28 | — | — | 1,632.04 | −2.7% |
| Other income | 168.39 | — | — | (84.64) | Turned profit |
| Total income | 1,755.67 | — | — | 1,547.39 | +13.5% |
| Profit before tax | 358.18 | — | — | 183.83 | +94.8% |
| Net profit for the period | 281.29 | — | — | 195.87 | +43.6% |
| EPS, basic (₹) | 9.97 | — | — | 6.94 | +43.7% |
| Net margin (%) | 17.7 | — | 12.0 |
Consolidated
- Filed with BSE
- 30 May 2019, 17:45 IST
- Board meeting
- 29 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 May 2019, 17:45 IST
- Board meeting
- 29 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE